CRISPR Therapeutics AG (CRSP) EBIT (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of EBIT data on file, last reported at -$130.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 12.25% year-over-year to -$130.2 million; the trailing twelve-month figure through Mar 2026 stood at -$646.4 million (down 36.25% YoY), and the FY2025 full-year result was -$664.6 million, down 42.44% from the prior year.
• EBIT improved to -$130.2 million in Q1 2026, from -$154.8 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $69.6 million in Q4 2023 to a low of -$229.3 million in Q2 2025.
• A 5-year average of -$126.9 million and a median of -$132.4 million in 2023 frame the typical range for EBIT.
• Across the five-year window, EBIT surged 152.9% in 2023 and sank 192.82% in 2024, its largest moves.
• Tracing CRSP's EBIT over 5 years: stood at -$131.5 million in 2022, then soared by 152.9% to $69.6 million in 2023, then slumped by 192.82% to -$64.6 million in 2024, then sank by 139.62% to -$154.8 million in 2025, then grew by 15.84% to -$130.2 million in 2026.
• Business Quant data shows CRSP's EBIT at -$130.2 million in Q1 2026, -$154.8 million in Q4 2025, and -$132.1 million in Q3 2025.